Drug Description in Trials / DrugBank / KEGG DRUG

  

Search results

No. Drug (Description in trials) DrugBank KEGG DRUG KEGG GENES KEGG PATHWAY Disease ID
1[over-encapsulated Irbesartan]
(D00523)		[1] Irbesartan[1] Irbesartan (D00523) 💬 [1] AGTR1 💬 [17] AGE-RAGE signaling pathway in diabetic complications, Adrenergic signaling in cardiomyocytes, Aldosterone synthesis and secretion, Apelin signaling pathway, Calcium signaling pathway, Coronavirus disease, Cortisol synthesis and secretion, Cushing syndrome, Diabetic cardiomyopathy, Hormone signaling, Neuroactive ligand-receptor interaction, Pathways in cancer, Phospholipase D signaling pathway, Renin secretion, Renin-angiotensin system, Vascular smooth muscle contraction, cGMP-PKG signaling pathway 💬[1] 222 💬
2Irbesartan
(D00523)		[1] Irbesartan[1] Irbesartan (D00523) 💬 [1] AGTR1 💬 [17] AGE-RAGE signaling pathway in diabetic complications, Adrenergic signaling in cardiomyocytes, Aldosterone synthesis and secretion, Apelin signaling pathway, Calcium signaling pathway, Coronavirus disease, Cortisol synthesis and secretion, Cushing syndrome, Diabetic cardiomyopathy, Hormone signaling, Neuroactive ligand-receptor interaction, Pathways in cancer, Phospholipase D signaling pathway, Renin secretion, Renin-angiotensin system, Vascular smooth muscle contraction, cGMP-PKG signaling pathway 💬[6] 57, 66, 167, 168, 222, 223 💬
3Irbesartan 150-300mg capsules daily for 6 months
(D00523)		[1] Irbesartan[1] Irbesartan (D00523) 💬 [1] AGTR1 💬 [17] AGE-RAGE signaling pathway in diabetic complications, Adrenergic signaling in cardiomyocytes, Aldosterone synthesis and secretion, Apelin signaling pathway, Calcium signaling pathway, Coronavirus disease, Cortisol synthesis and secretion, Cushing syndrome, Diabetic cardiomyopathy, Hormone signaling, Neuroactive ligand-receptor interaction, Pathways in cancer, Phospholipase D signaling pathway, Renin secretion, Renin-angiotensin system, Vascular smooth muscle contraction, cGMP-PKG signaling pathway 💬[1] 167 💬
4Irbesartan tablets
(D00523)		[1] Irbesartan[1] Irbesartan (D00523) 💬 [1] AGTR1 💬 [17] AGE-RAGE signaling pathway in diabetic complications, Adrenergic signaling in cardiomyocytes, Aldosterone synthesis and secretion, Apelin signaling pathway, Calcium signaling pathway, Coronavirus disease, Cortisol synthesis and secretion, Cushing syndrome, Diabetic cardiomyopathy, Hormone signaling, Neuroactive ligand-receptor interaction, Pathways in cancer, Phospholipase D signaling pathway, Renin secretion, Renin-angiotensin system, Vascular smooth muscle contraction, cGMP-PKG signaling pathway 💬[2] 66, 222 💬
5Irbesartan tablets (Approved in the USA. Reference listed drug Avapro) NDC # 43547-0374-03
(D00523)		[1] Irbesartan[1] Irbesartan (D00523) 💬 [1] AGTR1 💬 [17] AGE-RAGE signaling pathway in diabetic complications, Adrenergic signaling in cardiomyocytes, Aldosterone synthesis and secretion, Apelin signaling pathway, Calcium signaling pathway, Coronavirus disease, Cortisol synthesis and secretion, Cushing syndrome, Diabetic cardiomyopathy, Hormone signaling, Neuroactive ligand-receptor interaction, Pathways in cancer, Phospholipase D signaling pathway, Renin secretion, Renin-angiotensin system, Vascular smooth muscle contraction, cGMP-PKG signaling pathway 💬[2] 66, 222 💬
6Irbesartan tablets (Approved in the USA. Reference listed drug Avapro) NDC # 43547-0374-03Product Name: over-encapsulated 75 mg Irbesartan TabletsPharmaceutical Form: Capsule, hardINN or Proposed INN: IrbesartanCAS Number: 138402-11-6Other descriptive name: IRBESARTANConcentration unit: mg milligram(s)Concentration type: equalConcentration number: 75-
(D00523)		[1] Irbesartan[1] Irbesartan (D00523) 💬 [1] AGTR1 💬 [17] AGE-RAGE signaling pathway in diabetic complications, Adrenergic signaling in cardiomyocytes, Aldosterone synthesis and secretion, Apelin signaling pathway, Calcium signaling pathway, Coronavirus disease, Cortisol synthesis and secretion, Cushing syndrome, Diabetic cardiomyopathy, Hormone signaling, Neuroactive ligand-receptor interaction, Pathways in cancer, Phospholipase D signaling pathway, Renin secretion, Renin-angiotensin system, Vascular smooth muscle contraction, cGMP-PKG signaling pathway 💬[1] 222 💬
7Irbesartan tablets (NDC# 43547-0374-03 and NDC 43547-374-09, approved in the USA) Generic tablets distributed by Solco Healthcare US, LLCProduct Name: over-encapsulated Irbesartan TabletsPharmaceutical Form: Capsule, hardINN or Proposed INN: IrbesartanCAS Number: 138402-11-6Other descriptive name: IRBESARTANConcentration unit: mg milligram(s)Concentration type: equalConcentration number: 75-Trade Name: Irbesartan tabletsProduct Name: over-encapsulated Irbesartan TabletsPharmaceutical Form: Capsule, hardINN or Proposed INN: IrbesartanCAS Number: 138402-11-6Other descriptive name: IRBESARTANConcentration unit: mg milligram(s)Concentration type: equalConcentration number: 75-Product Name: SparsentanProduct Code: RE-021Pharmaceutical Form: TabletINN or Proposed INN: SparsentanCAS Number: 254740-64-2Current Sponsor code: RE-021Other descriptive name: SPARSENTANConcentration unit: mg milligram(s)Concentration type: equalConcentration number: 200-Trade Name: Irbesartan tablets (NDC# 31722-729-30 approved in the United states)Product Name: Over-encapsulated Irbesartan TabletsPharmaceutical Form: Capsule, hardCAS Number: 138402-11-6Other descriptive name: IRBESARTANConcentration unit: mg milligram(s)Concentration type: equalConcentration number: 75-Product Name: SparsentanProduct Code: RE-021Pharmaceutical Form: TabletINN or Proposed INN: SparsentanCAS Number: 254740-64-2Current Sponsor code: RE-021O
(D00523)		[1] Irbesartan[1] Irbesartan (D00523) 💬 [1] AGTR1 💬 [17] AGE-RAGE signaling pathway in diabetic complications, Adrenergic signaling in cardiomyocytes, Aldosterone synthesis and secretion, Apelin signaling pathway, Calcium signaling pathway, Coronavirus disease, Cortisol synthesis and secretion, Cushing syndrome, Diabetic cardiomyopathy, Hormone signaling, Neuroactive ligand-receptor interaction, Pathways in cancer, Phospholipase D signaling pathway, Renin secretion, Renin-angiotensin system, Vascular smooth muscle contraction, cGMP-PKG signaling pathway 💬[1] 222 💬
8Irbesartan tabletsProduct Name: over-encapsulated Irbesartan TabletsPharmaceutical Form: Capsule, hardINN or Proposed INN: IrbesartanCAS Number: 138402-11-6Other descriptive name: IRBESARTANConcentration unit: mg milligram(s)Concentration type: equalConcentration number: 75-Trade Name: Irbesartan tabletsProduct Name: over-encapsulated Irbesartan TabletsPharmaceutical Form: Capsule, hardINN or Proposed INN: IrbesartanCAS Number: 138402-11-6Other descriptive name: IRBESARTANConcentration unit: mg milligram(s)Concentration type: equalConcentration number: 75-Product Name: SparsentanProduct Code: RE-021Pharmaceutical Form: TabletINN or Proposed INN: SparsentanCAS Number: 254740-64-2Concentration unit: mg milligram(s)Concentration type: equalConcentration number: 200-Trade Name: Irbesartan tabletsProduct Name: Over-encapsulated Irbesartan TabletsPharmaceutical Form: Capsule, hardINN or Proposed INN: IrbesartanCAS Number: 138402-11-6Other descriptive name: IRBESARTANConcentration unit: mg milligram(s)Concentration type: equalConcentration number: 75-Product Name: SparsentanProduct Code: RE-021Pharmaceutical Form: TabletINN or Proposed INN: SparsentanCAS Number: 254740-64-2Concentration unit: mg milligram(s)Concentration type: equalConcentration number: 400-
(D00523)		[1] Irbesartan[1] Irbesartan (D00523) 💬 [1] AGTR1 💬 [17] AGE-RAGE signaling pathway in diabetic complications, Adrenergic signaling in cardiomyocytes, Aldosterone synthesis and secretion, Apelin signaling pathway, Calcium signaling pathway, Coronavirus disease, Cortisol synthesis and secretion, Cushing syndrome, Diabetic cardiomyopathy, Hormone signaling, Neuroactive ligand-receptor interaction, Pathways in cancer, Phospholipase D signaling pathway, Renin secretion, Renin-angiotensin system, Vascular smooth muscle contraction, cGMP-PKG signaling pathway 💬[1] 222 💬
9Irbesartan tabletsProduct Name: over-encapsulated Irbesartan TabletsPharmaceutical Form: Capsule, hardINN or Proposed INN: IrbesartanCAS Number: 138402-11-6Other descriptive name: IRBESARTANConcentration unit: mg milligram(s)Concentration type: equalConcentration number: 75-Trade Name: Irbesartan tabletsProduct Name: over-encapsulated Irbesartan TabletsPharmaceutical Form: Capsule, hardINN or Proposed INN: IrbesartanCAS Number: 138402-11-6Other descriptive name: IRBESARTANConcentration unit: mg milligram(s)Concentration type: equalConcentration number: 75-Product Name: SparsentanProduct Code: RE-021Pharmaceutical Form: TabletINN or Proposed INN: SparsentanCAS Number: 254740-64-2Concentration unit: mg milligram(s)Concentration type: equalConcentration number: 200-Trade Name: Irbesartan tabletsProduct Name: Over-encapsulated Irbesartan TabletsPharmaceutical Form: Capsule, hardINN or Proposed INN: IrbesartanCAS Number: 138402-11-6Other descriptive name: IRBESARTANConcentration unit: mg milligram(s)Concentration type: equalConcentration number: 75-Product Name: SparsentanProduct Code: RE-021Pharmaceutical Form: TabletINN or Proposed INN: SparsentanCAS Number: 254740-64-2Current Sponsor code: RE-021Other descriptive name: SPARSENTANConcentration unit: mg milligram(s)Concentration type: equalConcentration number: 400-
(D00523)		[1] Irbesartan[1] Irbesartan (D00523) 💬 [1] AGTR1 💬 [17] AGE-RAGE signaling pathway in diabetic complications, Adrenergic signaling in cardiomyocytes, Aldosterone synthesis and secretion, Apelin signaling pathway, Calcium signaling pathway, Coronavirus disease, Cortisol synthesis and secretion, Cushing syndrome, Diabetic cardiomyopathy, Hormone signaling, Neuroactive ligand-receptor interaction, Pathways in cancer, Phospholipase D signaling pathway, Renin secretion, Renin-angiotensin system, Vascular smooth muscle contraction, cGMP-PKG signaling pathway 💬[1] 222 💬
10Irbesartan tabletsProduct Name: over-encapsulated Irbesartan TabletsPharmaceutical Form: Capsule, hardINN or Proposed INN: IrbesartanCAS Number: 138402-11-6Other descriptive name: IRBESARTANConcentration unit: mg milligram(s)Concentration type: equalConcentration number: 75-Trade Name: Irbesartan tabletsProduct Name: over-encapsulated Irbesartan TabletsPharmaceutical Form: Capsule, hardINN or Proposed INN: IrbesartanCAS Number: 138402-11-6Other descriptive name: IRBESARTANConcentration unit: mg milligram(s)Concentration type: equalConcentration number: 75-Product Name: SparsentanProduct Code: RE-021Pharmaceutical Form: TabletINN or Proposed INN: SparsentanCAS Number: 254740-64-2Current Sponsor code: RE-021Other descriptive name: SPARSENTANConcentration unit: mg milligram(s)Concentration type: equalConcentration number: 200-Trade Name: Irbesartan tabletsProduct Name: Over-encapsulated Irbesartan TabletsPharmaceutical Form: Capsule, hardINN or Proposed INN: IrbesartanCAS Number: 138402-11-6Other descriptive name: IRBESARTANConcentration unit: mg milligram(s)Concentration type: equalConcentration number: 75-Product Name: SparsentanProduct Code: RE-021Pharmaceutical Form: TabletINN or Proposed INN: SparsentanCAS Number: 254740-64-2Current Sponsor code: RE-021Other descriptive name: SPARSENTANConcentration unit: mg milligram(s)Concentration type: equalConcentration number: 400-
(D00523)		[1] Irbesartan[1] Irbesartan (D00523) 💬 [1] AGTR1 💬 [17] AGE-RAGE signaling pathway in diabetic complications, Adrenergic signaling in cardiomyocytes, Aldosterone synthesis and secretion, Apelin signaling pathway, Calcium signaling pathway, Coronavirus disease, Cortisol synthesis and secretion, Cushing syndrome, Diabetic cardiomyopathy, Hormone signaling, Neuroactive ligand-receptor interaction, Pathways in cancer, Phospholipase D signaling pathway, Renin secretion, Renin-angiotensin system, Vascular smooth muscle contraction, cGMP-PKG signaling pathway 💬[1] 222 💬
11Over-encapsulated 150 mg Irbesartan Tablets
(D00523)		[1] Irbesartan[1] Irbesartan (D00523) 💬 [1] AGTR1 💬 [17] AGE-RAGE signaling pathway in diabetic complications, Adrenergic signaling in cardiomyocytes, Aldosterone synthesis and secretion, Apelin signaling pathway, Calcium signaling pathway, Coronavirus disease, Cortisol synthesis and secretion, Cushing syndrome, Diabetic cardiomyopathy, Hormone signaling, Neuroactive ligand-receptor interaction, Pathways in cancer, Phospholipase D signaling pathway, Renin secretion, Renin-angiotensin system, Vascular smooth muscle contraction, cGMP-PKG signaling pathway 💬[1] 66 💬
12Over-encapsulated 75 mg Irbesartan Tablets
(D00523)		[1] Irbesartan[1] Irbesartan (D00523) 💬 [1] AGTR1 💬 [17] AGE-RAGE signaling pathway in diabetic complications, Adrenergic signaling in cardiomyocytes, Aldosterone synthesis and secretion, Apelin signaling pathway, Calcium signaling pathway, Coronavirus disease, Cortisol synthesis and secretion, Cushing syndrome, Diabetic cardiomyopathy, Hormone signaling, Neuroactive ligand-receptor interaction, Pathways in cancer, Phospholipase D signaling pathway, Renin secretion, Renin-angiotensin system, Vascular smooth muscle contraction, cGMP-PKG signaling pathway 💬[1] 222 💬
13Over-encapsulated Irbesartan
(D00523)		[1] Irbesartan[1] Irbesartan (D00523) 💬 [1] AGTR1 💬 [17] AGE-RAGE signaling pathway in diabetic complications, Adrenergic signaling in cardiomyocytes, Aldosterone synthesis and secretion, Apelin signaling pathway, Calcium signaling pathway, Coronavirus disease, Cortisol synthesis and secretion, Cushing syndrome, Diabetic cardiomyopathy, Hormone signaling, Neuroactive ligand-receptor interaction, Pathways in cancer, Phospholipase D signaling pathway, Renin secretion, Renin-angiotensin system, Vascular smooth muscle contraction, cGMP-PKG signaling pathway 💬[1] 222 💬
14Over-encapsulated Irbesartan Tablets
(D00523)		[1] Irbesartan[1] Irbesartan (D00523) 💬 [1] AGTR1 💬 [17] AGE-RAGE signaling pathway in diabetic complications, Adrenergic signaling in cardiomyocytes, Aldosterone synthesis and secretion, Apelin signaling pathway, Calcium signaling pathway, Coronavirus disease, Cortisol synthesis and secretion, Cushing syndrome, Diabetic cardiomyopathy, Hormone signaling, Neuroactive ligand-receptor interaction, Pathways in cancer, Phospholipase D signaling pathway, Renin secretion, Renin-angiotensin system, Vascular smooth muscle contraction, cGMP-PKG signaling pathway 💬[2] 66, 222 💬